Screening of possible biomarkers and therapeutic targets in kidney renal clear cell carcinoma: Evidence from bioinformatic analysis

被引:3
|
作者
Peng, Longfei [1 ]
Cao, Zhangjun [1 ]
Wang, Qi [1 ]
Fang, Lu [1 ]
Yan, Songbai [1 ]
Xia, Dian [1 ]
Wang, Jinyou [1 ]
Bi, Liangkuan [1 ]
机构
[1] Anhui Med Univ, Hosp 2, Dept Urol, Hefei, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
关键词
microarray datasets; differentially expressed genes; Protein-protein interaction network; hub gene; renal cell carcinoma (RCC) clear cell renal cell carcinoma (CCRCC);
D O I
10.3389/fonc.2022.963483
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Renal cell carcinoma (RCC), as one of the most common urological malignancies, has many histologic and molecular subtypes, among which clear cell renal cell carcinoma (ccRCC) is one of the most common causes of tumor-related deaths. However, the molecular mechanism of ccRCC remains unclear. In order to identify the candidate genes that may exist in the occurrence and development of ccRCC, microarray datasets GSE6344, GSE16441, GSE36895, GSE53757 and GSE76351 had been downloaded from Gene Expression Omnibus (GEO) database. Apart from that, the differentially expressed genes (DEGs) were screened through Bioinformatics & Evolutionary Genomics. In addition, the protein-protein interaction network (PPI) was constructed, and the module analysis was performed using STRING and Cytoscape. By virtue of DAVID online database, GO/KEGG enrichment analysis of DEGs was performed. Consequently, a total of 118 DEGs were screened, including 24 up-regulated genes and 94 down-regulated genes. The plug-in MCODE of Cytoscape was adopted to analyze the most significant modules of DEGs. What's more, the genes with degree greater than 10 in DEGs were selected as the hub genes. The overall survival (OS) and disease progression free survival (DFS) of 9 hub genes were analyzed through GEPIA2 online platform. As shown by the survival analysis, SLC34A1, SLC12A3, SLC12A1, PLG, and ENO2 were closely related to the OS of ccRCC, whereas SLC34A1 and LOX were closely related to DFS. Among 11 SLC members, 6 SLC members were highly expressed in non-cancerous tissues (SLC5A2, SLC12A1, SLC12A3, SLC34A1, SLC34A2, SLC34A3). Besides, SLC12A5 and SLC12A7 were highly expressed in ccRCC. Furthermore, SLC12A1-A7, SLC34A1 and SLC34A3 were closely related to OS, whereas SLC12A2/A4/A6/A7 and SLC34A1/A3 were closely related to DFS. In addition, 5 algorithms were used to analyze hub genes, the overlapping genes were AQP2 and KCNJ1. To sum up, hub gene can help us understand the molecular mechanism of the occurrence and development of ccRCC, thereby providing a theoretical basis for the diagnosis and targeted therapy of ccRCC.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Emerging Targets in Clear Cell Renal Cell Carcinoma
    Chen, Yu-Wei
    Rini, Brian, I
    Beckermann, Kathryn E.
    CANCERS, 2022, 14 (19)
  • [32] Bioinformatic identification of key genes and analysis of prognostic values in clear cell renal cell carcinoma
    Luo, Ting
    Chen, Xiaoyi
    Zeng, Shufei
    Guan, Baozhang
    Hu, Bo
    Meng, Yu
    Liu, Fanna
    Wong, Taksui
    Lu, Yongpin
    Yun, Chen
    Hocher, Berthold
    Yin, Lianghong
    ONCOLOGY LETTERS, 2018, 16 (02) : 1747 - 1757
  • [33] Bioinformatic identification of renal cell carcinoma microenvironment-associated biomarkers with therapeutic and prognostic value
    Zeng, Qingquan
    Zhang, Weiyi
    Li, Xiaoling
    Lai, Jianqiang
    Li, Zuwei
    LIFE SCIENCES, 2020, 243
  • [34] Bioinformatics analysis and verification of gene targets for renal clear cell carcinoma
    Li, Feng
    Jin, Yi
    Pei, Xiaolu
    Guo, Peiyuan
    Dong, Keqin
    Wang, Haoyuan
    Chen, Yujia
    Guo, Peng
    Meng, Ling-Bing
    Wang, Zhiyu
    COMPUTATIONAL BIOLOGY AND CHEMISTRY, 2021, 92
  • [35] In vivo characterization of glutamine metabolism identifies therapeutic targets in clear cell renal cell carcinoma
    Kaushik, Akash K.
    Tarangelo, Amy
    Boroughs, Lindsey K.
    Ragavan, Mukundan
    Zhang, Yuanyuan
    Wu, Cheng-Yang
    Li, Xiangyi
    Ahumada, Kristen
    Chiang, Jui-Chung
    Tcheuyap, Vanina T.
    Saatchi, Faeze
    Do, Quyen N.
    Yong, Cissy
    Rosales, Tracy
    Stevens, Christina
    Rao, Aparna D.
    Faubert, Brandon
    Pachnis, Panayotis
    Zacharias, Lauren G.
    Hieu Vu
    Cai, Feng
    Mathews, Thomas P.
    Genovese, Giannicola
    Slusher, Barbara S.
    Kapur, Payal
    Sun, Xiankai
    Merritt, Matthew
    Brugarolas, James
    DeBerardinis, Ralph J.
    SCIENCE ADVANCES, 2022, 8 (50)
  • [36] Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinoma
    Sonpavde, Guru
    Willey, Christopher D.
    Sudarshan, Sunil
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2014, 23 (03) : 305 - 315
  • [37] EXPLOITING NOVEL THERAPEUTIC TARGETS TO BLOCK METASTASIS OF CLEAR CELL RENAL CELL CARCINOMA (RCC)
    Rudzinski, Jan
    Govindasamy, Natasha
    Stoletov, Konstantin
    Fairey, Adrian
    Lewis, John
    JOURNAL OF UROLOGY, 2019, 201 (04): : E207 - E208
  • [38] OSkirc: a web tool for identifying prognostic biomarkers in kidney renal clear cell carcinoma
    Xie, Longxiang
    Wang, Qiang
    Dang, Yifang
    Ge, Linna
    Sun, Xiaoxiao
    Li, Ning
    Han, Yali
    Yan, Zhongyi
    Zhang, Lu
    Li, Yongqiang
    Zhang, Haiyu
    Guo, Xiangqian
    FUTURE ONCOLOGY, 2019, 15 (27) : 3103 - 3110
  • [39] Antioxidants and Therapeutic Targets in Ovarian Clear Cell Carcinoma
    Amano, Tsukuru
    Murakami, Atsushi
    Murakami, Takashi
    Chano, Tokuhiro
    ANTIOXIDANTS, 2021, 10 (02) : 1 - 15
  • [40] The promising novel biomarkers and candidate small molecule drugs in kidney renal clear cell carcinoma: Evidence from bioinformatics analysis of high-throughput data
    Zhang, Bo
    Wu, Qiong
    Wang, Ziheng
    Xu, Ran
    Hu, Xinyi
    Sun, Yidan
    Wang, Qiuhong
    Ju, Fei
    Ren, Shiqi
    Zhang, Chenlin
    Qin, Lin
    Ma, Qianqian
    Zhou, You Lang
    MOLECULAR GENETICS & GENOMIC MEDICINE, 2019, 7 (05):